Mehr über EndoPredict®

Publikationen

Alle Anforderungen für die CE-Markierung erfüllt:

Durch Klicken auf die Unterpunkte erhalten Sie einen Link zu der entsprechenden Literaturstelle.

Scientific Validity
  • Validated in 4 clinical trials
  • Prospectiv-retrospectiv approach
  • Level of Evidence 1 (LoE1)
  • Excellent performance in clinical chemotherapy trial
  • outperformed Oncotype DX in Head to Head comparison
  • Clinical Performance
  • Identifies large low risk group
  • Adds relevant prognostic information
  • Outperforming standard parameter
  • Predicts early AND late metastasis
  • Analytical Performance
  • Fulfills essential requirements of IVDD 98/79/EG
  • High precision
  • Robust de-central performance
  • Can be performed on core biopsies and surgical specimens
  • Clinical
    Utility
  • Increases low risk group with excellent outcome
  • Reduces chemotherapy associated costs
  • Part of german & internat. guidelines
  • Performed in more than 60 pathologies


  • Scientific Validity

    • Dubsky P, Filipits M, Jakesz R, Rudas M, Singer C, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M,Gehrmann M, Petry C, Weber K, Kronenwett R, Brase JC, Gnant M. (2012) EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol Epub http://annonc.oxfordjournals.org/content/24/3/640.long
    • Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Muller V, Janicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M. (2011) A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clinical Cancer Research 17: 6012-6020. http://clincancerres.aacrjournals.org/content/17/18/6012.long
    • M Martin, J C Brase, L Calvo, K Krappmann, M Ruiz-Borrego, K Fisch, A Ruiz, K E Weber, B Munarriz, C Petry, C A Rodriguez, R Kronenwett, C Crespo, E Alba, E Carrasco, M Casas, R Caballero, A Rodriguez-Lescure. Clinical validation of the EndoPredict test in node-positive chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM/9906 trial. Breast Cancer Res. 2014 Apr 12;16(2):R38. http://breast-cancer-research.com/content/16/2/R38/abstract

    Clinical Performance

    • P Dubsky, J C Brase, R Jakesz, M Rudas, C F Singer, R Greil, O Dietze, I Luisser, E Klug, R Sedivy, M Bachner, D Mayr, M Schmidt, M C Gehrmann, C Petry, K E Weber, K Fisch, R Kronenwett, M Gnant, M Filipits. (2013) The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients. British Journal of Cancer advance online publication 24 October 2013; doi: 10.1038/bjc.2013.671 http://www.nature.com/bjc/journal/vaop/ncurrent/pdf/bjc2013671a.pdf
    • Dubsky P, Filipits M, Jakesz R, Rudas M, Singer C, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M,Gehrmann M, Petry C, Weber K, Kronenwett R, Brase JC, Gnant M. (2012) EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol Epub http://annonc.oxfordjournals.org/content/24/3/640.long
    • Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Muller V, Janicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M. (2011) A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clinical Cancer Research 17: 6012-6020. http://clincancerres.aacrjournals.org/content/17/18/6012.long
    • M Martin, J C Brase, L Calvo, K Krappmann, M Ruiz-Borrego, K Fisch, A Ruiz, K E Weber, B Munarriz, C Petry, C A Rodriguez, R Kronenwett, C Crespo, E Alba, E Carrasco, M Casas, R Caballero, A Rodriguez-Lescure. Clinical validation of the EndoPredict test in node-positive chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM/9906 trial. Breast Cancer Res. 2014 Apr 12;16(2):R38. http://breast-cancer-research.com/content/16/2/R38/abstract

    Clinical Utility

    • Brase JC, Kronenwett R, Petry C, Denkert C, Schmidt M. (2013) From High-Throuput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigen Test for Breast Cancer Prognosis. MDPI Epub www.mdpi.com/2076-3905/2/3/243/pdf
    • Müller B, Keil E, Lehmann A, Winzer K-J, Richter-Ehrenstein C, Prinzler J, Bangemann N, Reles A, Stadie S, Schoenegg W, Eucker J, Schmidt M, Lippek F, Jöhrens K, Pahl S, Sinn B, Budczies J, Dietel M, Denkert C. (2013) The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions. PLOS ONE. Epub http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0068252
    • Dubsky P, Filipits M, Jakesz R, Rudas M, Singer C, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M,Gehrmann M, Petry C, Weber K, Kronenwett R, Brase JC, Gnant M. (2012) EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol Epub http://annonc.oxfordjournals.org/content/24/3/640.long
    • Blank P R, Filipits M, Dubsky P, Gutzwiller F, Lux M P, Brase J C, Weber K E, Rudas M, Greil R, Loibl S, Szucs T D,  Kronenwett R, Schwenkglenks M,  Gnant M. (2014) Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients. PharmacoEconomics. http://link.springer.com/article/10.1007/s40273-014-0227-x

    Analytical Performance

    • Kronenwett R, Bohmann K, Prinzler J, Sinn BV, Haufe F, Roth C, Averdick M, Ropers T, Windbergs C, Brase JC, Weber KE, Fisch K, Müller BM, Schmidt M, Filipits M, Dubsky P, Petry C, Dietel M, Denkert C. (2012) Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test. BMC Cancer, accepted http://www.biomedcentral.com/1471-2407/12/456
    • Denkert C, Kronenwett R, Schlake W, Bohmann K, Penzel R, Weber KE, Höfler H, Lehmann U, Schirmacher P, Specht K, Rudas M, Kreipe HH, Schraml P, Schlake G, Bago-Horvath Z, Tiecke F, Varga Z, Moch H, Schmidt M, Prinzler J, Kerjaschki D, Sinn B, Müller B, Filipits M, Petry C, Dietel M. (2012) Decentral gene expression analysis for ER+/Her2- breast cancer – results of a proficiency testing program for the EndoPredict assay. Virchows Arch. 460: 251-259. http://link.springer.com/article/10.1007%2Fs00428-012-1204-4
    • Müller BM, Brase JC, Haufe F, Weber KE, Budzies J, Petry C, Prinzler J, Kronenwett R, Dietel M, Denkert C. (2012) Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections. J Clin Pathol.Epub http://jcp.bmj.com/content/65/7/660.long
    • C Poremba, J Uhlendorff, B M Pfitzner, G Hennig, K Bohmann, H Bojar, V Krenn, J C Brase, F Haufe, M Averdick, M Dietel, R Kronenwett, C Denkert. (2014) Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer. Virchows Arch. http://link.springer.com/article/10.1007/s00428-014-1652-0

    Sonstige Publikationen

    • Muller BM, Kronenwett R, Hennig G, Euting H, Weber K, Bohmann K, Weichert W, Altmann G, Roth C, Winzer KJ, Kristiansen G, Petry C, Dietel M, Denkert C. (2011) Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer. Diagnostic Molecular Pathology 20: 1-10. http://journals.lww.com/molecularpathology/pages/articleviewer.aspx?year=2011&issue=03000&article=00001&type=abstract
    • Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Torne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G. (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. Journal of Clinical Oncology 28: 105-113. http://jco.ascopubs.org/content/28/1/105.long
    • Brase JC, Schmidt M, Fischbach T, Sultmann H, Bojar H, Koelbl H, Hellwig B, Rahnenfuhrer J, Hengstler JG, Gehrmann MC. (2010) ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clinical Cancer Research 16: 2391-2401. http://clincancerres.aacrjournals.org/content/16/8/2391.long
    • Bohmann K, Hennig G, Rogel U, Poremba C, Mueller BM, Fritz P, Stoerkel S, Schaefer KL. (2009) RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods. Clinical Chemistry 55: 1719-1727. http://www.clinchem.org/content/55/9/1719.long

    Artikel in Fachzeitschriften:

    • Wagner, S. (2013) 10 Jahre Tamoxifen - für welche Patientin? Frauenarzt.

    • Denkert, C. (2013) Genexpressionsanalyse beim Mammakarzinom. Der Pathologe. http://link.springer.com/article/10.1007/s00292-013-1781-2
    • Varga Z, Sinn P, Fritzsche F, von Hochstetter A Noske A, Schraml P, Tausch C, Trojan A,Moch H. (2013) Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer. PloS one 2013, 8, e58483. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0058483
    • Denkert C, Huober J, Loibl S, Prinzler J, Kronenwett R, Darb-Esfahani S, Brase JC, Solbach C, Mehta K, Fasching PA, Sinn BV, Engels K, Reinisch M, Hansmann ML, Tesch H, von Minckwitz G, Untch M. (2013) HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Res. http://breast-cancer-research.com/content/15/1/R11
    • Sinn BV, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Tesch H, Kronenwett R, Hoffmann G, Belau A, Thommsen C, Holzhausen HJ, Grasshoff ST, Baumann K, Mehta K, Dietel M, Loibl S. (2013) Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer. Ann. Oncol. http://annonc.oxfordjournals.org/content/24/9/2316.long
    • Kotoula V, Kalogeras KT, Kouvatseas G, Televantou D, Kronenwett R, Wirtz RM,Fountzilas G. (2012) Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research, Virchows Arch. http://annonc.oxfordjournals.org/content/24/9/2316.long
    • Linardou H, Kalogeras KT, Kronenwett R, Kouvatseas G, Wirtz RM, Zagouri F, Gogas H, Christodoulou C, Koutras AK, Samantas E, Pectasides D, Bafaloukos D, Fountzilas G. (2012) The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial, Breast cancer research. http://breast-cancer-research.com/content/14/6/R145
    • Denkert C, Loibl S, Kronenwett R, Budczies J, von Torne C, Nekljudova V, Darb-Esfahani S, Solbach C, Sinn BV, Petry C, Muller BM, Hilfrich J, Altmann G, Staebler A, Roth C, Ataseven B, Kirchner T, Dietel M, Untch M, von Minckwitz G. (2012) RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy, Ann Oncol. http://annonc.oxfordjournals.org/content/24/3/632.long
    • Pliarchopoulou K, Kalogeras KT, Kronenwett R, Wirtz RM, Eleftheraki AG, Batistatou A, Bobos M, Soupos N, Polychronidou G, Gogas H, Samantas E, Christodoulou C, Makatsoris T, Pavlidis N, Pectasides D, Fountzilas G. (2012) Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial, Cancer Chemother Pharmacol. http://link.springer.com/article/10.1007%2Fs00280-012-2002-z
    • Darb-Esfahani S, Kronenwett R, von Minckwitz G, Denkert C, Gehrmann M, Rody A, Budczies J, Brase JC, Mehta MK, Bojar H, Ataseven B, Karn T, Weiss E, Zahm DM, Khandan F, Dietel M, Loibl S. (2012) Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer, Br J Cancer. 107, 1892-900. http://www.nature.com/bjc/journal/v107/n11/full/bjc2012475a.html
    • Razis E, Kalogeras KT, Kotoula V, Eleftheraki AG, Nikitas N, Kronenwett R, Timotheadou E, Christodoulou C, Pectasides D, Gogas H, Wirtz RM, Makatsoris T, Bafaloukos D, Aravantinos G, Televantou D, Pavlidis N, Fountzilas G. (2012) Improved Outcome of High-Risk Early HER2 Positive Breast Cancer With High CXCL13-CXCR5 Messenger RNA Expression. Clinical Breast Cancer 12: 183-193. http://www.sciencedirect.com/science/article/pii/S1526820912000821
    • Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Boehm D, Gebhard S, Petry I, Lebrecht A, Cadenas C, Marchan R, Stewart JD, Solbach C, Holmberg L, Edlund K, Kultima HG, Rody A, Berglund A, Lambe M, Isaksson A, Botling J, Karn T, Muller V, Gerhold-Ay A, Cotarelo C, Sebastian M, Kronenwett R, Bojar H, Lehr HA, Sahin U, Koelbl H, Gehrmann M, Micke P, Rahnenfuhrer J, Hengstler JG. (2012) A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 18: 2695-2703. http://clincancerres.aacrjournals.org/content/18/9/2695.long
    • Fountzilas G, Valavanis C, Kotoula V, Eleftheraki AG, Kalogeras KT, Tzaida O, Batistatou A, Kronenwett R, Wirtz RM, Bobos M, Timotheadou E, Soupos N, Pentheroudakis G, Gogas H, Vlachodimitropoulos D, Polychronidou G, Aravantinos G, Koutras A, Christodoulou C, Pectasides D, Arapantoni P. (2012) HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. Journal of Translational Medicine 10: 10: http://www.translational-medicine.com/content/10/1/10
    • Psyrri A, Kalogeras KT, Kronenwett R, Wirtz RM, Batistatou A, Bournakis E, Timotheadou E, Gogas H, Aravantinos G, Christodoulou C, Makatsoris T, Linardou H, Pectasides D, Pavlidis N, Economopoulos T, Fountzilas G. (2011) Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer - A Hellenic Cooperative Oncology Group (HeCOG) Study. Annals of Oncology 23: 1422-1427. http://annonc.oxfordjournals.org/content/23/6/1422.long
    • Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G. (2012) Triple negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy - A translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial. Cancer Chemotherapy and Pharmacology 69: 533-546. http://link.springer.com/article/10.1007%2Fs00280-011-1730-9
    • Pentheroudakis G, Batistatou A, Kalogeras KT, Kronenwett R, Wirtz RM, Bournakis E, Eleftheraki AG, Pectasides D, Bobos M, Papaspirou I, Kamina S, Gogas H, Koutras AK, Pavlidis N, Fountzilas G. (2011) Prognostic utility of beta-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study. Breast Cancer Research and Treatment 127: 179-193. http://link.springer.com/article/10.1007%2Fs10549-011-1427-0
    • Noske A, Loibl S, Darb-Esfahani S, Roller M, Kronenwett R, Muller BM, Steffen J, von Toerne C, Wirtz R, Baumann I, Hoffmann G, Heinrich G, Grasshoff ST, Ulmer HU, Denkert C, von Minckwitz G. (2011) Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). Breast Cancer Research and Treatment 126: 109-117. http://link.springer.com/article/10.1007%2Fs10549-010-1316-y
    • Hennig G, Gehrmann M, Stropp U, Brauch H, Fritz P, Eichelbaum M, Schwab M, Schroth W. (2010) Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression. Clinical Chemistry 56: 1845-1853. http://www.clinchem.org/content/56/12/1845.long
    • Johannes M, Brase JC, Frohlich H, Gade S, Gehrmann M, Falth M, Sultmann H, Beissbarth T. (2010) Integration of pathway knowledge into a reweighted recursive feature elimination approach for risk stratification of cancer patients. Bioinformatics 26: 2136-2144: http://bioinformatics.oxfordjournals.org/content/26/17/2136.long
    • Gehrmann M, Schmidt M, Brase JC, Roos P, Hengstler JG. (2008) Prediction of paclitaxel resistance in breast cancer: is CYP1B1*3 a new factor of influence? Pharmacogenomics 9: 969-974. http://www.futuremedicine.com/doi/abs/10.2217/14622416.9.7.969?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed&
    • Petry C, Gehrmann M, von Torne C, Weber K, Stropp U, Hennig G. (2008) Predictive and prognostic markers of breast cancer. Molecular biological analysis of fixed tumor tissue. Der Pathologe 29 Suppl 2: 181-183. http://link.springer.com/article/10.1007%2Fs00292-008-1081-4
    • Stephan Schwers, Elke Reifenberger, Alexandre Izmailov, Kerstin Bohmann. (2009), A high-sensitivity, medium density and target amplification-free planar waveguide microarray system for gene expression analysis from FFPE tissue, Clinical Chemistry 55 (11): 1995-2003. http://www.clinchem.org/content/55/11/1995.long

    Präsentationen auf Fachkongressen:

    • Ettl J, Große Lackmann K, Hapfelmeier A, Klein E, Paepke S, Petry C, Specht K, Höfler H, Kiechle M. Prospective comparison of uPA/PAI-1 and endopredict-clin score in ER-positive, HER2-negative breast cancer: Impact on risk stratification and treatment decisions. ASCO 2013
    • Blank P, Schwenkglenks M, Dubsky P, Filipits M, Gutzwiller F, Lux MP, Brase JC, Kronenwett R, Szucs TD, Gnant M. Health economic analysis of guideline and gene expression signature-based risk stratification of distant recurrence in early breast cancer patients. IMPAKT Meeting 2013
    • Dubsky P, Brase JC, Fisch K, Jakesz R, Singer CF, Greil R, Dietze O, Weber KE, Petry C, Kronenwett R, Rudas M, Knauer M, Gnant M, Filipits M.(2012) The EndoPredict score identifies late distant metastases in ER+/HER2- breast cancer patients. Abstract, San Antonio Breast Cancer Symposium 2012
    • Martin M, Brase JC, Ruiz-Borrego M, Krappmann K, Munarriz B, Fisch K, Ruiz A, Weber KE, Crespo C, Petry C, Rodriguez CA, Kronenwett R, Calvo L, Alba E, Carrasco E, Casas M, Caballero R, Rodriguez-Lescure A.(2012) Prognostic performance of the EndoPredict score in nodepositive chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM/9906 trial. Abstract, San Antonio Breast Cancer Symposium 2012
    • Filipits M, Dubsky PC, Rudas M, Brase JC, Kronenwett R, Weber KE, Petry C, Schmidt M, Luisser I, Klug E, Gnant M (2012) Impact of the EndoPredict-clin score on risk stratification in ER-positive, HER2-negative breast cancer after considering clinical guidelines. Abstract, ASCO 2012
    • Brase JC, Gehrmann MC, Petry C, Weber KE, Schmidt M, Kölbl H, Brauch H, Schwab M, Müller V, Jänicke F, Rody A, Kaufmann M, Filipits M, Gnant M, Denkert C, Loibl S, von Minckwitz G, Kronenwett R (2011) The EndoPredict Score is a response predictor for neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. Abstract, San Antonio Breast Cancer Symposium 2011
    • Kronenwett R, Stropp U, Briasoulis E, Gehrmann M, Razis E, Hennig G, Bafaloukos D, Wirtz RM, Economopoulos T, Fountzilas G (2009) Utility of a multigene prognostic algorithm in combination with TP53 expression for prediction of benefit from adjuvant taxane-containing chemotherapy in node-positive breast cancer patients. Abstract, ASCO 2009
    • von Minckwitz G, Budczies J, Loibl S, Darb-Esfahani S, Kaufmann M, Huober J, Engels K, Denkert C, Kronenwett R, von Toerne C (2009) Validated 3 Gene Signature Predicts Response to Neo-Adjuvant Chemotherapy in Luminal Breast Cancer - Results from GeparTrio and GeparQuattro. Abstract, San Antonio Breast Cancer Symposium 2009
    • Kronenwett R, Kalogeras KT, Stropp U, Weber K, Dafni U, Gehrmann M, Pectasides D, von Toerne C, Papakostas P, Wirtz RM, Fountzilas G (2008) Prognostic algorithm identified in node-negative early breast cancer patients predicts outcome also in node-positive patients treated with adjuvant chemotherapy. Abstract, San Antonio Breast Cancer Symposium 2008
    • Schmidt M, Tramm T, Böhm D, Kyndi M, Lehr HA, Alstner J, Kölbl H, Stropp U, von Törne C, Weber K, Hennig G, Gehrmann M, Overgaard J (2008) Molecular breast cancer prognosis in node negative early breast cancer. Abstract, San Antonio Breast Cancer Symposium 2008
    • Brase JC, Schmidt M, Hengstler JG, Von Toerne C, Koelbl H, Gehrmann M (2007) Single agent in vitro drug sensitivity of molecular breast cancer subtypes defined by gene expression analysis. Abstract, San Antonio Breast Cancer Symposium 2007